There is a possibility to expand HRD targeted therapy using LP-184 in other cancers such as NSCLC and AML (5) as well as subgroups of the rare cancer medulloblastoma carrying germline mutations in PALB2 and BRCA2 (39). The gene discussed is PALB2; the disease is cancer.